April 4, 2019 09:13 AM EDTUpdated May 28, 12:32 PM
R&D

As­traZeneca’s asth­ma drug Fasen­ra looks promis­ing for a set of rare chron­ic im­mune dis­eases

John Carroll

Editor & Founder

Just 16 months af­ter the FDA ap­proved As­traZeneca’s Fasen­ra for a se­vere form of asth­ma, in­ves­ti­ga­tors at the NIH have found that the drug ap­pears …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times